This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Health technology
Thrombolytic therapy with tissue plasminogen activator versus streptokinase for acute myocardial infarction.
Type of intervention
Treatment.
Economic study type
Cost-effectiveness analysis and cost-utility analysis.
Study population
Patients with acute myocardial infarction undergoing thrombolytic therapy.
Setting
Hospital. The economic study was carried out in the USA in co-operation with several international institutes.
Dates to which data relate
Effectiveness data related to the period between 1971 and 1992. Cost data related to 1993 prices.
Source of effectiveness data
Synthesis of studies.
Modelling
A Cox proportional-hazards model was used in estimating long-term health outcomes.
Outcomes assessed in the review
Life years saved.
Study designs and other criteria for inclusion in the review
The estimate for clinical outcomes was based on the results of the GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) randomised trial study that compared four thrombolytic strategies by estimating 30-day mortality rates. The authors of the present paper carried out an observational study to estimate life expectancy based on the survival rates of the GUSTO study by using the Duke Cardiovascular Disease Database.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data Not stated.
Number of primary studies included
One randomised clinical trial and an observational study were combined.
Methods of combining primary studies
The observational study provided information on the long-term clinical outcomes based on projections on the shortterm survival rate estimates of the randomised trial study.
Investigation of differences between primary studies
Results of the review
The study estimated a life expectancy of 15.27 years for patients treated with streptokinase and a life expectancy of 15.41 years for patients treated with t-PA.
Measure of benefits used in the economic analysis
Life years gained and Quality Adjusted Life Years (QALYs). Patients' utility was measured by telephone interviews one year after treatment.
Direct costs
All the costs were discounted. Some costs and quantities were reported separately. One-year and long-term direct health service costs were used. Initial hospitalisation costs were calculated in two ways: from the Duke Transition One costaccounting system and from Medicare DRG reimbursement rates. Thrombolytic agent costs were calculated from the Drug Topics Red Book average of 1993 wholesale prices and from the average drug costs in 16 randomly selected hospitals in the GUSTO study. Follow-up hospitalisation costs were estimated from Medicare DRG reimbursement rates for North Carolina. Physicians' fees for initial and follow-up hospitalisation were calculated from the Medicare fee schedule for North Carolina. The authors assumed that pharmacy handling and preparation costs and drugadministration costs were equal for the two regimens. It was also assumed that there were no cost differences between the two treatment groups after one year.
